Albert David was incorporated in the year 1938. The company is a part of Kothari group.

Albert David, which has decades of illustrious presence in the health care industry, manufactures pharmaceutical formulations and bulk drugs, infusion solutions and oral solids, disposable syringes and needles and herbal formulations. The company exports these products to Vietnam, Russia, Belarus, Egypt, Bangladesh, Kenya, Tanzania, Uganda, Sudan, Ethiopia, Nigeria, Zaire, Haiti, Brazil, Canada, USA, UK, Netherlands and Germany as the company is a WHO-approved supplier.

It also has DMF for the bulk drugs, Tolbutamide and Chlorpropamide with the US Food and Drugs Administration (USFDA). The manufacturing facility for these products has been inspected and validated by the US drug regulator.

The manufacturing plants of the company are located at Ghaziabad near New Delhi, Kolkata and Mandideep near Bhopal.

The company`s amino acid range under the brand name of Alamin contains pure crystalline amino acid of high international standards manufactured under a unique technology, which conforms to WHO and FAO recommendations. In the herbal segment, the company sells its products under brand names like Adliv, which is a hepato protective and Siotone capsule, which is the only adaptogen indicated for stress.

ADL has tie-ups with Ajinomoto Co and Roussel Morishita Co of Japan for manufacturing and marketing a wide range of crystalline amino acid infusion solutions, oral solids and liquids in India.

Products offered by the Company:

The company is operating in major therapeutic segments that include:

Analgesics/AntiInflammatory
Anti-Bacterials
Anti-Ulcerants
Dermatologicals
Anxiolytics
Large Volume Parenteral
Disposable Syringes & Needles
Herbal Drugs
Nutrition
Neurotropics
Placental Extracts
Anthelmintic
Haemostati
Cough Preparations
Laxatives
Skeletal Relaxants
Anti-Arthiritic / Chondroprotective Agents.

Future Plans:

The company will explore the possibilities for export of its IV fluids, small volume parenterals and disposable syringes in addition to its existing range.
It will concentrate on product line extension for its flagship brand Placentrex by bringing in newer formulations and looking for a new therapeutic area of usage.
Future expansion in the herbal product range will be focused in the area of women`s healthcare.
ADL is planning to enter newer therapeutic areas like dermatological and ophthalmological segments.
Furthermore, it will also strengthen its presence in the gastrointestinal segments and in the areas of pain management.
The company is also planning to launch newer products in the areas of nutritional, gynaecological and herbal medicine.

Market Cap	425 Cr	ROE	13.5%
P/E Ratio(TTM)	7.3	EPS(TTM)	0.0
P/B Ratio	1.3	Dividend Yield	1.2%
Industry P/E	41.3	Book Value	587.1
		Face Value	10.0

Fundamentals